258 related articles for article (PubMed ID: 8288676)
1. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Huland E; Heinzer H; Huland H
J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
[TBL] [Abstract][Full Text] [Related]
3. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter].
Heinzer H; Huland E; Aalamian M; Huland H
Urologe A; 1999 Sep; 38(5):466-73. PubMed ID: 10501705
[TBL] [Abstract][Full Text] [Related]
5. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
6. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.
Clark JI; Gaynor ER; Martone B; Budds SC; Manjunath R; Flanigan RC; Waters WB; Sosman JA
Clin Cancer Res; 1999 Sep; 5(9):2374-80. PubMed ID: 10499607
[TBL] [Abstract][Full Text] [Related]
7. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
Donskov F; von der Maase H; Henriksson R; Stiemer U; Wersäll P; Nellemann H; Hellstrand K; Engman K; Naredi P
Ann Oncol; 2002 Mar; 13(3):441-9. PubMed ID: 11996477
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
9. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
11. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma.
Huland E; Huland H; Heinzer H
J Urol; 1992 Feb; 147(2):344-8. PubMed ID: 1732590
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
Dillman RO; Wiemann MC; Tai DF; Depriest CB; Soori G; Stark JJ; Mahdavi K; Church CK
Cancer Biother Radiopharm; 2006 Apr; 21(2):130-7. PubMed ID: 16706633
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
Koulova L; Novik Y; Caliendo G; Wiernik P; Dutcher J
J Immunother; 2005; 28(6):576-81. PubMed ID: 16224275
[TBL] [Abstract][Full Text] [Related]
17. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
18. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.
Huland E; Heinzer H; Mir TS; Huland H
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S98-105. PubMed ID: 9457403
[TBL] [Abstract][Full Text] [Related]
19. Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma.
Lopez Hanninen E; Fenner M; Kirchner H; Deckert M; Duensing S; Menzel T; Poliwoda H; Atzpodien J
Cancer Biother; 1993; 8(4):301-6. PubMed ID: 7804371
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
Vogelzang NJ; Lipton A; Figlin RA
J Clin Oncol; 1993 Sep; 11(9):1809-16. PubMed ID: 8355047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]